|
|
Effectiveness and safety of ustekinumab intensification at 90 Mg every four weeks In Crohn's disease: a multicenter study
Mathurin Fumery
,
Laurent Peyrin-Biroulet
,
Stéphane Nancey
,
Romain Altwegg
,
Cyrielle Gilletta
,
et al.
Article dans une revue
hal-02959922v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease
Parambir S. Dulai
,
Aurélien Amiot
,
Laurent Peyrin-Biroulet
,
Vipul Jairaith
,
Mélanie Serrero
,
et al.
Article dans une revue
hal-03552288v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn’s Disease
Nassim Hammoudi
,
Dominique Cazals-Hatem
,
Claire Auzolle
,
Charlotte Gardair
,
Marjolaine Ngollo
,
et al.
Article dans une revue
hal-02193633v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 Years
Gilles Boschetti
,
Stephane Nancey
,
Fady Daniel
,
Benjamin Pariente
,
Eric Lerebours
,
et al.
Article dans une revue
hal-03553388v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study
Mathurin Fumery
,
Antoine Defrance
,
Xavier Roblin
,
Romain Altwegg
,
Benedicte Caron
,
et al.
Article dans une revue
hal-03911091v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|